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AIM
Interleukin (IL)-7 signalling modulates T cell activity and is implicated in numerous autoimmune diseases. The present study
investigated the safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of GSK2618960, an
IL-7 receptor-α subunit (CD127) monoclonal antibody.
METHODS
A double-blind (sponsor-unblind) study of a single intravenous infusion of either GSK2618960 (0.6 mg kg–1 or 2.0 mg kg–1) or
placebo was carried out in 18 healthy subjects over 24 weeks.
RESULTS
GSK2618960 was well tolerated; there were no serious or signiﬁcant adverse events. The observed half-life was 5 (±1) days
(2.0 mg kg–1), with nonlinear pharmacokinetics. Full receptor occupancy (>95%) was observed until day 8 (0.6 mg kg–1) and day
22 (2.0 mg kg–1). Maximal inhibition of IL-7-mediated signal transducer and activator of transcription 5 (STAT5) phosphorylation
was observed in 5/6 subjects until day 22 (2.0 mg kg–1). Mean circulating IL-7 and soluble receptor (CD127) levels were increased
above baseline during days 2 and 15 (0.6 mg kg–1) and days 2 and 22 (2.0 mg kg–1). No meaningful changes were observed in
absolute numbers or proportions of immune cell populations or inﬂammatory cytokine proﬁles (IL-6, tumour necrosis factor-α,
interferon-γ, IL-2). Persistent antidrug antibodies (ADAs) were detected in 5/6 subjects administered a dose of 0.6 mg kg–1
(neutralizing in 2/6) and in 6/6 subjects administered 2.0 mg kg–1 (neutralizing in 5/6).
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CONCLUSION
GSK2618960 was well tolerated and blocked IL-7 receptor signalling upon full target engagement. Although there was no
discernible impact on peripheral T cell subsets in healthy subjects, GSK2618960 may effectively modulate the autoinﬂammatory
activity of pathogenic T cells in diseased tissue. A relatively short half-life is likely the result of target-mediated rather than
ADA-mediated clearance.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Interleukin-7 (IL-7) and thymic stromal lymphopoietin share a common receptor component, CD127, and have been
implicated in several autoimmune and allergic inﬂammatory diseases, respectively.
• IL-7 signalling may promote the survival, activation and differentiation of lymphocytes.
WHAT THIS STUDY ADDS
• Single doses of GSK2618960 (0.6 mg kg–1 or 2.0 mg kg–1) were well tolerated, increased circulating IL-7 and soluble
CD127, and elicited antidrug antibodies with neutralizing capability, but did not have an impact on lymphocyte
populations, inﬂammatory cytokines or differentiation markers.
• Drug concentrations required for full in vivo receptor occupancy agreed with previous in vitro studies.
Introduction
An increasing body of both preclinical and clinical evidence
suggests that raised expression levels of interleukin (IL)-7
and/or the IL-7 receptor (IL-7R) are associated with
various disease states, including rheumatoid arthritis [1–3],
juvenile idiopathic arthritis [4], spondyloarthritis [5],
psoriasis [6], primary Sjögren’s syndrome [7–10], colitis
[11], type 1 diabetes [12, 13] and multiple sclerosis [14,
15]. Genome-wide association studies have also identiﬁed
genetic variations in IL-7R as a risk factor for some autoim-
mune diseases [16, 17].
IL-7 is a pleiotropic cytokine that is constitutively pro-
duced by stromal cells in nonhaematological tissues (intesti-
nal epithelium, lungs, skin, liver) as well as by lymphoid
tissue (thymus and bone marrow), and by lymphatic endo-
thelial cells [18, 19]. IL-7 plays a key role in T cell ontogeny
[20] and in the homeostatic maintenance of the peripheral
T cell pool [21]. Activation of the IL-7/IL-7R pathway in lym-
phocytes leads to survival (antiapoptotic activity), differenti-
ation of mature naïve and memory T cells, and proliferation
[19]. In addition, IL-7 plays a role in survival and function
of innate lymphoid cells, including natural killer cells [22],
lymphoid tissue inducer cells [23] and other diverse cell types
[19]. IL-7 promotes TH1 and TH17 effector cell function [8, 15,
24, 25], and stimulates cytotoxic activity of CD8+ T cells [26]
and the secretion of proinﬂammatory cytokines by mono-
cytes [27]. IL-7 also stimulates peripheral blood mononuclear
cells to secrete T cell-attracting cytokines [9], and acts via
CD4+ T cells and monocytes in co-culture to augment the ac-
tivation of B cells [28].
To explore the therapeutic utility of blocking IL-7 signal-
ling, a humanized Fc-disabled immunoglobulin G1 (IgG1)
monoclonal antibody (mAb) directed against the alpha com-
ponent (IL-7Rα; CD127) of the heterodimeric IL-7R
(GSK2618960) was developed. CD127 is also a component
of the thymic stromal lymphopoietin receptor (TSLPR) and
is required for competent TSLP signalling [29, 30]. The TSLPR
complex has been associated with a number of allergic in-
ﬂammatory diseases [30–32]. Therefore, GSK2618960 may
have the potential to inhibit both pharmacologies and may
have utility in autoimmune and allergic inﬂammatory
diseases. Although IL-7Rα signalling is crucial to most T
lymphocytes, regulatory T cells (Treg) exhibit relatively low-
to-undetectable expression of the receptor [33]. Thus, it was
hypothesized that blocking IL-7R signalling may selectively
spare Treg function while exerting inhibitory effects on other
potentially pathogenic T cell types, further supporting the ra-
tionale as a potential therapeutic target.
A ﬁrst-in-human study of single intravenous (IV) infu-
sions of GSK2618960 (ranging from 0.001 mg kg–1 to
0.15mg kg–1) demonstrated favourable safety and tolerability
proﬁles within which no antidrug antibodies (ADAs) were de-
tected (Study I7R116702; NCT01808482) [34, 35]. The pres-
ent study (Study 200 902) assessed the safety, tolerability,
pharmacokinetics (PK), target engagement, pharmacody-
namics (PD) and immunogenicity of two single ascending
doses of GSK2618960 in healthy subjects.
Methods
Study design
This was a phase I randomized, double-blind (sponsor-
unblind), placebo-controlled study performed in a single
centre in Cambridge, UK, between November 2014 and
September 2015. The study was conducted in accordance
with Good Clinical Practice and the Declaration of Helsinki
2013, and local regulations. The protocol was approved by
the local ethics committee (14/LO/1670, National Research
Ethics Service Committee, London, UK) and all study subjects
provided written informed consent. The study was registered
on Clinicaltrials.gov (identiﬁer: NCT02293161).
Two single ascending dose cohorts (A and B), each
consisting of nine healthy subjects, were sequentially ran-
domized (2:1) to receive either GSK2618960 or placebo as
a single IV infusion over 1 h. The randomization schedule
was generated by the sponsor’s clinical statistics department
using validated proprietary software. The IV infusion was
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prepared by pharmacy staff and dispensed in a blinded
fashion. Both the active IV infusion and placebo were
colourless.
Both sentinel and staged dosing were implemented. A
dose escalation committee was employed (sponsor unblind:
only the central medical monitors were to review unblinded
safety data when deemed necessary). The starting dose level
of 0.6 mg kg–1 (Cohort A) was a fourfold increase over the
highest dose level tested in the ﬁrst-in-human study
(I7R116702; see Supporting Information). The dose level of
GSK2618960 that was predicted to provide no more than
30 days’ maximal receptor occupancy (RO) was 2.0 mg kg–1
(planned for Cohort B). The no observed adverse effect dose
level in the 4-weekly repeat IV bolus Good Laboratory Prac-
tice cynomolgus monkey toxicity study was 300 mg kg–1
(GlaxoSmithKline data on ﬁle).
Subjects were screened up to 28 days (42 days for those
subjects consenting to vaccination) before admission to the
clinical unit on day 1 (predose). All subjects remained in
the unit for at least 24 h following dosing, and were moni-
tored at least weekly during the period of full RO and then ev-
ery 4 weeks thereafter until week 24 (in case of latent
lymphopenia).
Stopping criteria were: a serious adverse event (SAE); a
lymphocyte count<0.5 × 109 l–1 (sustained for 2 weeks); infu-
sion reactions (National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events grade 3 or greater) or evidence
of immune activation leading to moderate to severe clinical
manifestations in one subject administered active treatment;
and AEs of moderate or severe intensity (consistent across
subjects and reasonably attributable to study drug). The liver
stopping criterion was alanine aminotransferase levels ≥3 ×
the upper limit of normal.
Subjects
Healthy males or females of nonchildbearing potential,
18–65 years of age with normal laboratory values, body
weight ≥50 kg, body mass index 19.0–32.0 kg m–2 and a
conﬁrmed positive vaccination status for childhood vac-
cines (or consent to vaccination) were enrolled. Subjects
were excluded if they had a history of a signiﬁcant disease,
had received a live vaccine within 1 month of screening (or
were planning to receive a live vaccine within 6 months of
completing dosing), or had a history of, or were at high
risk for, tuberculosis.
Study assessments and procedures
Safety and tolerability assessments (co-primary endpoints).
Vital signs, routine haematology, clinical chemistry
(including proinﬂammatory cytokines) and urinalysis
(predose, and on days 1, 2, 3, 4, 8, 15, 22, 29, 43, 57, 85,
113, 141 and 169), full physical examination (baseline, and
on days 2 and 169), 12-lead electrocardiogram (ECG) (days
1, 2, 15 and 169), and 24-h Holter ECG (day 1) were
performed; AEs were recorded throughout the study.
Virology screening and serology (for vaccination status)
were also undertaken and a baseline blood sample for
comparative retrospective viral testing was archived in case
of symptoms of infection.
PK assessments. PK proﬁling of GSK2618960 was conducted
on plasma samples using a validated electrochemiluminescence
immunoassay (ECLIA), with a lower limit of quantiﬁcation of
50 ng ml–1.
PD/biomarker assessments. The extent and duration of
GSK2618960 target engagement was assessed by evaluating
RO on CD3+ T lymphocytes in a whole-blood ﬂow
cytometry assay. Full RO was deﬁned as the occupation of
>95% IL-7Rα molecules on peripheral blood T cells. To
assess whether GSK2618960 target engagement effectively
blocked IL-7R signalling, phosphorylation levels of signal
transducer and activator of transcription 5 (STAT5)
expression in CD3+ CD4+ T cells were assessed by ﬂow
cytometry after ex vivo incubation of whole blood with
exogenous IL-7 stimulant.
Total plasma IL-7 levels (free and bound to soluble IL-7Rα)
were measured using a validated assay kit (Meso-Scale Discov-
ery, Rockville, MD, USA; see Supporting Information). Total
soluble IL-7Rα (CD127) levels in the plasma were measured
using a validated ECLIA method (Meso Scale Discovery; see
Supporting Information). Plasma TSLP levels were measured
by a validated Singulex Erenna homogeneous assay format
(see Supporting Information).
The effect of GSK2618960 on circulating lymphocyte
populations was assessed using two approaches: (i) ﬂow cy-
tometry in whole blood: T, CD4 (and CD8), Th1/ Th2/
Th17, Tc1/Tc2/Tc17, cytotoxic T, Treg, naïve T, central and
effector memory T, recent thymic emigrants, natural killer
and B cells; and (ii) epigenetic quantiﬁcation of CD3/TH17,
CD3/FoxP3, CD3/TfH and B cells was performed at Epiontis
(Berlin, Germany).
The effect of GSK2618960 on circulating inﬂammatory
markers was assessed in the plasma: for IL-17A and IL-17F, a
bead-based Singulex Erenna immunoassay kit (EMD
Millipore, St Charles, MO, USA) was used; for interferon- γ
(IFN-γ), IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13
and tumour necrosis factor-α, a validated 10-plex assay kit
(Meso Scale Discovery) was used.
Immunogenicity (incidence and titre of ADAs) was
assessed on days 1, 15 and 22 (Cohort B), 29, 85 and 169
(week 24) and analysed using a validated bridging ECLIA
method (Meso Scale Discovery; see Supporting Information).
ADAs were characterized for their neutralizing capability and
titre. The titre was deﬁned as the reciprocal of the maximum
dilution still yielding a positive response (> the screening
cut point).
Statistical analysis
No formal statistical hypothesis was tested. The sample size of
18 subjects was chosen based on feasibility considerations.
The safety population comprised all subjects who received
at least one dose of study drug (or partial administration)
and was used for assessment of safety, PD/biomarkers and im-
munogenicity. The PK population comprised all subjects in
the safety population for whom ≥80% of the study drug vol-
ume was administered and a PK sample was acquired. Plasma
GSK2618960 concentration–time data were analysed by
noncompartmental methods (WinNonlin 6.3; Certara,
Princeton, NJ, USA). A locally weighted regression (locally
J. Ellis et al.
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estimated scatterplot smoothing; LOESS) was used to explore
the PK/PD relationship between concentration of
GSK2618960 and RO as a post hoc analysis. For data analysis,
placebo-treated subjects from each dose cohort were com-
bined as the placebo treatment group (n = 6).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY [36], and are permanently archived in
the Concise Guide to PHARMACOLOGY 2017/18 [37].
Results
Study population results
All 18 subjects were treated per protocol, completed the study
andwere included in the safety and PK populations (Figure 1).
Demographics and baseline characteristics are summarized in
Table 1. Concomitant medications were taken by approxi-
mately 78% of subjects and were in accordance with the
protocol.
Safety
There were no clinically signiﬁcant safety or tolerability
concerns following a single IV dose of either GSK2618960
0.6 mg kg–1 or 2.0 mg kg–1. There were no deaths or SAEs,
and none of the subjects were withdrawn owing to AEs. A
total of 54 AEs were reported as either of mild (n = 50) or
moderate (n = 4) intensity, and all resolved prior to study
completion without the need for long-term follow-up. The
most commonly reported AEs were nasopharyngitis (nine
subjects) and headache (ﬁve subjects), which resolved fully;
eight subjects across the three treatment groups used paracet-
amol as needed. Although nasopharyngitis, headache and
conjunctivitis were deemed to be causally related to the study
drug (blinded assessment), the frequencies of
nasopharyngitis and headache were spread across the three
treatment groups (Table 2). No trends or clinically signiﬁcant
signals were observed for any of the laboratory parameters, vi-
tal signs or ECGs.
PK
The main PK parameters estimated by noncompartmental
analysis are shown in Table 3. After administration
of GSK2618960 0.6 mg kg–1, the mean clearance was
0.6 ml h–1 kg–1 and the mean volume of distribution was
52.3 ml kg–1; after administration of GSK2618960 2.0 mg
kg–1, the mean clearance was 0.3 ml h–1 kg–1 and the mean
volume of distribution was 55.9 ml kg–1. The decreased
clearance at increased dose was likely to have been a result
of saturating target-mediated drug disposition.
Figure 2 shows the GSK2618960 individual plasma con-
centrations. In the 0.6 mg kg–1 group, the mean concentra-
tion (n = 6) at 7 days post-infusion was 2.05 μg ml–1 (range:
1.46–2.70 μg ml–1); at 14 days post-infusion, the mean value
(n = 3) was 0.055 μg ml–1 (range: 0–0.14 μg ml–1) (three sam-
ples were below the limit of quantitation and were set to zero
for the calculation). In the 2.0 mg kg–1 group, the mean con-
centration (n = 6) at 14 days and 21 days post-infusion was
8.14 μg ml–1 (range: 6.08–9.66 μg ml–1) and 3.05 μg ml–1
(range: 0.42–5.18 μg ml–1), respectively; and 5/6 subjects
had a plasma concentration >1 μg ml–1.
Target engagement
Following dosing of GSK2618960 0.6 mg kg–1, RO >95%
was observed for all subjects at 1 h and day 8 (Figure 3).
After this time, individual subjects’ RO values diminished
at different rates, and by day 15 the mean value was 39.3%
(range: 0–75.9%). Following dosing of GSK2618960 2 mg
kg–1, RO >95% was observed at 1 h and last observed in
5/6 subjects on day 22. After this time, all individual sub-
jects’ RO values diminished at different rates, and by day
29 the mean value was 60.3% (range: 24.2–97.6%).
PD
Inhibition of IL-7R signalling (phosphorylated STAT5). IL-7R
signal inhibition (derived from residual ex vivo IL-7-driven
STAT5 phosphorylation) was maximally observed at 1 h
postdose and last observed on day 8 in the 0.6 mg kg–1
group (see caveat in Supporting Information) and last
observed in 5/6 subjects in the 2.0 mg kg–1 group on day 22
(Figure 4).
Effect of GSK2618960 on the phosphorylation of STAT5.
Addition of GSK2618960 to CD3+ CD4+ T cells (prior to
dosing, and in the absence of IL-7) induced the
phosphorylation of STAT5 (receptor agonism). The mean of
replicate determinations was 6.94% (standard deviation
2.79%) of the maximum achieved with IL-7 stimulation
alone (positive control, 100%) and values were observed in
17/18 subjects (data not shown). There was no change in
receptor agonism (as deﬁned by STAT5 phosphorylation)
over time (assessed ex vivo using exogenous GSK2618960)
when comparing baseline samples with those obtained
throughout the Cohort B treatment period (samples from
Did not meet inclusion/
exclusion criteria, n = 10
Back-up, n = 2
Screened 
N = 30
Randomized
N = 18
Completed n = 6
(safety population n = 6;
PK population n = 6)
Completed n = 6
(safety population n = 6;
PK population n = 6)
Completed n = 6
(safety population n = 6)
GSK2618960
0.6 mg kg–1
n = 6
(Cohort A)
GSK2618960
2.0 mg kg–1
n = 6
(Cohort B)
Placebo
n = 6
Figure 1
Subject disposition. PK, pharmacokinetic
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Cohort A were not evaluable owing to a procedural
technicality – see Supporting Information).
Exploratory markers
Circulating biomarkers: IL-7, TSLP and soluble IL-7Rα
(sCD127). Baseline IL-7 levels ranged from 2.23 pg ml–1
to 26.45 pg ml–1. In subjects receiving GSK2618960
0.6 mg kg–1, the mean increase in IL-7 levels was ﬁrst
detected at 4 h (Figure 5A) (and by which time full target
engagement had already been achieved). IL-7 concentration
reached peak levels during days 2–15, and returned to
baseline by day 22. In subjects receiving GSK2618960
2.0 mg kg–1, IL-7 concentration reached peak levels during
days 2–22 and returned to baseline by day 29 (Figure 5A).
Only four subjects had measurable TSLP levels pre- and
postdose (range: 9.49–80.55 pg ml–1), with no signiﬁcant
change from baseline following dosing (data not shown).
Figure 5B illustrates circulating sCD127 levels (free and
drug bound) before and after treatment (baseline range:
1.02–8.49 ng ml–1). Levels were increased from baseline dur-
ing days 8–15 and returned to baseline by day 22 in the
0.6 mg kg–1 group, and during days 22–29, with a return to
baseline levels by day 43 in the 2.0 mg kg–1 group.
Circulating lymphocyte populations. Except for B cells
(CD45+, CD3, CD19+), there were no consistent changes
in the ﬂow cytometric assessment of either the absolute
numbers or percentages in any of the cell lineages in either
of the two GSK2618960 or placebo groups from baseline.
There was an unexpected, small, transient decrease in
circulating B cells across all three treatment groups from
baseline to day 8. The mean group absolute values (CD19+
as a percentage of total lymphocytes) at these time points
and the change from baseline (± standard deviation) were:
placebo, from 13.1% to 11.8% (1.3 ± 2.1%); 0.6 mg kg–1,
from 10.8% to 8.9% (1.9 ± 1.2%); and 2.0 mg kg–1, from
9.5% to 7.1% (2.5 ± 1.2%). Notably, treatment with
GSK2618960 did not appear to change the absolute number
of Tregs (CD45+ CD3+ CD4+ CD25high CD127). CD25
and programmed death-1 activation markers on selected cell
lineages did not change consistently.
Epigenetic quantiﬁcation of cell subtypes corroborated
that there were no consistent changes in the speciﬁc cell sub-
types selected, but that there were small transient unexpected
decreases in circulating B cells.
Inflammatory markers. Proinﬂammatory cytokine plasma
levels measured 4 h postdose did not indicate an effect of
Table 1
Summary of subject demographics and baseline characteristics (safety population)
Demographics Placebo (N = 6) GSK2618960 0.6 mg kg–1 (N = 6) GSK2618960 2.0 mg kg–1 (N = 6)
Age, years 30.3 (9.2) 30.3 (5.2) 36.7 (7.8)
Sex, n (%)
Female 0 (0) 0 (0) 0 (0)
Male 6 (100) 6 (100) 6 (100)
Body mass index, kg m–2 28.9 (2.5) 25.1 (2.8) 26.6 (2.9)
Height, cm 173.7 (8.4) 184.2 (5.5) 178.83 (8.4)
Weight, kg 87.9 (14.6) 85.6 (14.1) 85.2 (10.5)
Ethnicity, n (%)
Hispanic or Latino 0 (0) 0 (0) 0 (0)
Not Hispanic or Latino 6 (100) 6 (100) 6 (100)
Race, n (%)
White – Arabic/North African Heritage 1 (17) 0(0) 0 (0)
White –White/Caucasian/European Heritage 5 (83) 6 (100) 6 (100)
Values given are mean (standard deviation) unless speciﬁed otherwise
Table 2
Summary of all adverse events deemed drug related (safety population)
Adverse event Placebo (N = 6) GSK2618960 0.6 mg kg–1 (N = 6) GSK2618960 2.0 mg kg–1 (N = 6)
Nasopharyngitis 3 (50%) 4 (67%) 2 (33%)
Headache 2 (33%) 3 (50%) 0 (0%)
Conjunctivitis 1 (17%) 0 (0%) 0 (0%)
J. Ellis et al.
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Figure 2
GSK2618960 plasma concentrations in individual subjects following a single intravenous infusion. Symbols represent individual subjects. The
dashed horizontal line represents the lower limit of quantiﬁcation (LLQ = 50 ng ml–1). BLQ, below the limit of quantiﬁcation
Table 3
Summary statistics of derived plasma GSK2618960 PK parameters
Parameter GSK2618960 treatment Meana SD Median Min Max
AUC(0–inf)
(h*μg ml–1)
0.6 mg kg–1
2.0 mg kg–1
1005.5
6858.2
127.7
988.0
994.9
6619.1
827
5467
1165
8235
AUC(0–t)
(h*μg ml–1)
0.6 mg kg–1
2.0 mg kg–1
924.0
6615.0
148.8
989.5
939.1
6315.1
693
5414
1117
7900
CL
(ml h–1 kg–1)
0.6 mg kg–1
2.0 mg kg–1
0.6
0.3
0.08
0.04
0.6
0.3
0.5
0.2
0.7
0.4
Cmax
(μg ml–1)
0.6 mg kg–1
2.0 mg kg–1
11.2
43.2
1.5
7.6
11.1
41.0
9.00
36.1
13.3
57.8
Vss
(ml kg–1)
0.6 mg kg–1
2.0 mg kg–1
52.3
55.9
7.6
4.8
50.5
55.0
46.3
50.5
67.2
63.8
t½
(h)
0.6 mg kg–1
2.0 mg kg–1
57.4
123.0
7.6
26.8
56.6
126.9
48.0
86.8
68.1
155.0
tmax
(h)
0.6 mg kg–1
2.0 mg kg–1
2.5
3.0
1.2
2.7
2.0
2.0
1.1
1.0
4.0
8.0
AUC, area under the concentration–time curve; CL, systemic clearance of parent drug; Cmax, maximum observed concentration; inf, inﬁnity; PK,
pharmacokinetic; SD, standard deviation; t, time of last observed quantiﬁable concentration; t½, terminal phase half-life; tmax, time of occurrence of
Cmax; Vss, volume of distribution at steady state
aArithmetic mean
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GSK2618960 on cytokine release. IL-8 was increased at
apparently random time points in some subjects, as was
IFN-γ. Throughout the study, there were no consistent
changes from baseline in either of the T cell differentiation
markers (IL-17A or IL-17F) or in the other cytokines
measured (levels remained undetectable).
Immunogenicity. Five of six subjects receiving GSK2618960
0.6 mg kg–1 developed ADAs (titre range: 4–2560) and all six
subjects receiving GSK2618960 2.0 mg kg–1 developed ADAs
(titre range: 4–5120). Among the ADA-positive subjects, 2/5
subjects receiving GSK2618960 0.6 mg kg developed NAbs
(titre range: 2–10) and 5/6 subjects receiving GSK2618960
2.0 mg kg–1 had NAbs (titre range: 4–40). ADAs were
persistent to day 169.
Discussion
There were neither safety nor tolerability concerns following
a 1-h IV infusion of either a single 0.6 mg kg–1 or 2.0 mg kg–1
dose of GSK2618960 in healthy subjects. From both a safety
and mechanistic viewpoint, there was neither a short- nor
long-term impact on T-lymphocyte counts or subpopulations
throughout the 24-week study period. There was an unex-
pected transient small decrease in B cells that could not easily
be explained but may have been due to a redistribution phe-
nomenon. Overall, there were no meaningful changes to
inﬂammatory cytokines or differentiation markers (e.g. IL-
17A and IL-17F).
GSK2618960 successfully blocked IL-7R signalling above
the threshold concentration (1 μg ml–1) required for full tar-
get engagement, as evidenced by total inhibition of STAT5
phosphorylation (in an ex vivo assay), and this corroborated
previous in vitro ﬁndings (data on ﬁle). Thus, GSK2618960
may prove effective in modulating the autoinﬂammatory
activity of pathogenic T cells in localized diseased tissue
(e.g. salivary glands in patients with Sjögren’s syndrome).
These observations are in agreement with a PK/PD study
reported by Kern et al. in cynomolgus monkeys [38],
showing that treatment with an IL-7Rα mAb prevents the
ability of IL-7 to initiate downstream signalling proximal
from the IL-7R, as evidenced by inhibition of STAT5
phosphorylation.
Importantly, GSK2618960 inhibited IL-7-induced phos-
phorylation of STAT5 in a manner that was in concordance
with drug exposure, target engagement and its proposed
mechanism of action.
The duration at which GSK2618960 exposures weremain-
tained (in vivo) above the in vitro ‘threshold’ of 1 μg ml–1
concentration and the understanding of consequential
drug PD were central to both the study rationale and to
the importance of deﬁning a starting dose and regimen
for future clinical studies in patients. The actual duration
of exposure above the threshold concentration believed to
achieve full RO was 7 days and 21 days (0.6 mg kg–1 and
Figure 3
Receptor occupancy of interleukin-7 receptor subunit-α (IL-7Rα) following a single administration of GSK2618960. Mean (± standard deviation)
values
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2.0 mg kg–1 doses, respectively), which was shorter than
originally predicted (11 days and 30 days). The half-life of
the 0.6 mg kg–1 and 2.0 mg kg–1 single doses administered
by IV infusion was 57.4 (±7.6) and 123.0 (±26.8) h,
respectively, which is relatively short when compared with
that of a typical mAb against soluble targets (21 days) [39].
Clearance by target-mediated drug disposition (TMDD) pro-
vides an additional, but saturable, clearance pathway for
Figure 4
Extent and duration of phosphorylated signal transducer and activator of transcription 5 (pSTAT5) signal inhibition in individual subjects follow-
ing a single 2.0 mg kg–1 intravenous infusion of GSK2618960. Percentage inhibition of pSTAT5 signal upon ex vivo interleukin-7 exposure.
Coloured symbols represent individual subjects
Figure 5
Circulating (A) interleukin-7 (IL-7) and (B) soluble IL-7 receptor-α subunit (CD127) in plasma following a single intravenous infusion of
GSK2618960. Mean (± standard deviation) values
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some antibodies [40]. Thus, it appears that the level of tar-
get expression and, consequently, the extent of TMDD
were higher than originally anticipated. Despite the low
level of target, the TMDD phenomena can still play a rele-
vant role in explaining nonlinear PK, and this is mainly
because of the high turnover of the target that contributes
to the saturable elimination of the antibody. The decreased
clearance rate of GSK2618960 at the higher dose level
would support this.
Target engagement (>95% RO) was achieved at a thresh-
old concentration of >1 μg ml–1, which corroborated the
in vivo PK and target engagement ﬁndings. The relationship
between PK and RO is illustrated in Figure 6, with the ﬁtted
LOESS curve superimposed. As was expected, the extent of
duration of target engagement (RO) correlated with the inhi-
bition of phosphorylation of STAT5.
Although ADAs had not been observed in the ﬁrst-in-
human study (I7R116702; dose levels 0.001–0.15 mg kg–1)
[34, 35], ADAs were ﬁrst observed in 5/6 subjects adminis-
tered a single IV infusion of GSK2618960 0.6 mg kg–1, and
in all six subjects administered GSK2618960 2.0 mg kg–1,
with higher titres generated in Cohort B (2.0 mg kg–1 dose)
compared with Cohort A (0.6 mg kg–1 dose) suggesting a
dose-response relationship. Of note is that one subject gener-
ated a high titre (5120) by week 12 (assessed in the absence of
circulating GSK2618960 and based on the titration results
during method validation). Subjects who developed high
and persistent titres of ADAs (7/12 across both cohorts) also
developed NAbs). Furthermore, GSK2618960-speciﬁc mem-
ory B cells were detected in a B cell enzyme-linked
immunospot assay (data not shown). Memory B cell activity
developed as early as day 29, and was observed in all of those
subjects who had developed ADAs by day 169. The frequency
of such events seemed to be dose dependent. Following com-
pletion of Study 200 902, antidrug antibodies were observed
in the 6-month cynomolgus monkey study. ADAs to human-
ized antibodies are not unexpected in nonhuman primates
and do not usually prevent progression to clinical develop-
ment. It was noted that the results of clinical trial
NCT02045732 (an anti-IL7R mAb) listed that 3/3 subjects ad-
ministered 0.25 mg kg–1 PF-06342674 developed ADAs [41].
Expression of target IL-7 receptor on antigen presenting cells
may increase the potential for immunogenicity, but there
is no direct evidence. Host-, disease- and product-speciﬁc
factors are known to inﬂuence immunogenicity – e.g.
amino acid sequence, number and strength of T cell epi-
topes, post-translational modiﬁcation, structural alterations
(aggregation, oxidation, deamidation, degradation), storage
conditions, production and puriﬁcation processes [42].
GSK2618960 exhibited a degree of (paradoxical) agonistic
potential in the present study (assessed ex vivo), which corrobo-
rated a previous observation in the ﬁrst-in-human study,
I7R116702 [34, 35]. Agonistic activity could be exacerbated
in vivo by an ADA response mediating crosslinking. However,
the data indicated that there was no change to baseline agonism
levels following a single-dose IV infusion. Further evaluation of
Figure 6
GSK2618960 plasma concentrations vs. receptor occupancy of interleukin-7 receptor subunit-α, for subjects in each treatment group with the
ﬁtted locally estimated scatterplot smoothing curve (post hoc analysis). Coloured symbols represent individual subjects. The vertical line represents
the lower limit of quantiﬁcation (50 ng ml–1). BLQ, below the lower limit of quantiﬁcation
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any impact of this phenomenon, using an optimized assay,
could be incorporated into repeat-dose studies in patients.
It was envisaged that the binding of GSK2618960 to both
sCD127 andmembrane IL-7Rα subunit (CD127) would set up
a dynamic equilibrium – ﬁrstly, by preventing the binding of
IL-7 to both forms of the receptor and, secondly, by reducing
IL-7 clearance through receptor-mediated internalization.
Given that IL-7 is constitutively expressed [43, 44], such a dy-
namic equilibrium might manifest as an increase in circulat-
ing levels of IL-7 to a new threshold level. Indeed, the
marked increase in the level of IL-7 from baseline, the dura-
tion of that increase, and the onset and rate of decline were
in concordance with drug dose, exposure and RO. These data
indicate that GSK2618960 blocked clearance of IL-7 through
inhibition of receptor-mediated internalization. Understand-
ing the longer-term impact of this (if any) will require repeat
dose studies.
Similarly, sCD127 was speculated to increase upon
complexing with GSK2618960 and have prolonged clearance
until the complex was metabolized/excreted. Irrespective of
the GSK2618960 dose, the rate of accumulation of sCD127
was slower than that of IL-7 (increased levels of sCD127 only
became apparent on day 2). Administration of the higher dose
of GSK2618960 (2.0 mg kg–1 vs. 0.6 mg kg–1) and, consequen-
tially, higher exposure, resulted in a relatively higher and lon-
ger duration of increase in circulating sCD127, as predicted.
These data suggest that sCD127 (like IL-7) accumulates upon
engagement of IL-7Rα by GSK2618960 and declines upon
drug clearance. Circulating low TSLP concentrations were
apparently unaffected following a single infusion of
GSK2618960 at either dose level, which seemed to corrobo-
rate the notion that the binding of TSLP to its cognate hetero-
dimeric receptor [cytokine receptor-like factor 2 (CLFR2)]
would be unlikely to be affected by GSK2618960, at least after
a single infusion in the short term.
The main limitation of the present study was the inability
to determine whether ADAs had an impact on GSK2618960
clearance. IgG antibodies, such as GSK2618960, typically
have a half-life of 21 days [39], which is unfortunately
coincidental with the ﬁrst experimental detection of ADAs,
and so did not enable the determination of whether emergent
ADAs had affected the extent and duration of drug
exposure/clearance. Interpretation of PK data was yet further
confounded by the single and relatively low dose levels tested
and whereby TMDD was rationally believed to have short-
ened the half-life. It is known that ADAs not only have the
potential to increase the overall clearance rate, but also may
interfere with the detection of free drug levels in PK assays
[45]. Further repeat-dose clinical studies will be required to
evaluate the impact of ADAs on GSK2618960 clearance.
To conclude, GSK2618960 was well tolerated when ad-
ministered to healthy subjects as a single IV infusion at a dose
capable of maintaining effective receptor blockade for up to
21 days. There were no SAEs, and no meaningful changes
were observed in any haematological or immune cell popula-
tions or in the selected cytokine proﬁles. Single doses of
GSK2618960 elicited ADAs with high incidence and persis-
tent titres, and there was evidence of neutralizing capability.
TMDD appeared to shorten the half-life of GSK2618960 as
compared with a typical IgG antibody. There was a clear
PK/PD relationship between the duration of GSK2618960
exposure above the threshold concentration required to have
an impact on important measures, such as the extent and du-
ration of target engagement, and such PDmeasures as the ex-
tent and duration of inhibition of STAT5 phosphorylation
and the duration of the increased levels of circulating IL-7
and sCD127. Further repeat-dose studies are warranted in pa-
tients, to properly assess the potential of GSK2618960 to have
an impact on T cells and other cell populations in inﬂamed
tissues and to evaluate any clinical improvement.
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